Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells
M. Rosenzweig et al., Induction of cytotoxic T lymphocyte and antibody responses to enhanced green fluorescent protein following transplantation of transduced CD34(+) hematopoietic cells, BLOOD, 97(7), 2001, pp. 1951-1959
Genetic modification of hematopoietic stem cells often results in the expre
ssion of foreign proteins in pluripotent progenitor cells and their progeny
. However, the potential for products of foreign genes introduced into hema
topoietic stem cells to induce host immune responses is not well understood
. Gene marking and induction of immune responses to enhanced green fluoresc
ent protein (eGFP) were examined in rhesus macaques that underwent nonmyelo
ablative irradiation followed by infusions of CD34(+) bone marrow cells tra
nsduced with a retroviral vector expressing eGFP, CD34(+) cells were obtain
ed from untreated animals or from animals treated with recombinant human gr
anulocyte colony-stimulating factor (G-CSF) alone or G-CSF and recombinant
human stem cell factor. Levels of eGFP-expressing cells detected by flow cy
tometry peaked at 0.1% to 0.5% of all leukocytes 1 to 4 weeks after transpl
antation. Proviral DNA was detected in 0% to 17% of bone marrow-derived col
ony-forming units at periods of 5 to 18 weeks after transplantation. Howeve
r, 5 of 6 animals studied demonstrated a vigorous eGFP-specific cytotoxic T
lymphocyte (CTL) response that was associated with a loss of genetically m
odified cells in peripheral blood, as demonstrated by both flow cytometry a
nd polymerase chain reaction. The eGFP-specific CTL responses were MHC-rest
ricted, mediated by CD8(+) lymphocytes, and directed against multiple epito
pes, eGFP-specific CTLs were able to efficiently lyse autologous CD34(+) ce
lls expressing eGFP, Antibody responses to eGFP were detected in 3 of 6 ani
mals. These data document the potential for foreign proteins expressed in C
D34(+) hematopoietic cells and their progeny to induce antibody and CTL res
ponses in the setting of a clinically applicable transplantation protocol.
(Blood, 2001;97:1951-1959) (C) 2001 by The American Society of Hematology.